{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:00:29Z","timestamp":1793826029693,"version":"4.6.1"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:sec id=\"ab-nrv230003-1\"><jats:title>Importance<\/jats:title><jats:p>The temporal association between the occurrence of neurological diseases, many autoimmune diseases, and vaccination against SARS-CoV-2 has been topically interesting and remains hotly debated both in the medical literature and the clinic. Given the very low incidences of these events both naturally occurring and in relation to vaccination, it is challenging to determine with certainty whether there is any causative association and most certainly what the pathophysiology of that causation could be.<\/jats:p><\/jats:sec><jats:sec id=\"ab-nrv230003-2\"><jats:title>Observations<\/jats:title><jats:p>Data from international cohorts including millions of vaccinated individuals suggest that there is a probable association between the adenovirus-vectored vaccines and Guillain-Barr\u00e9 syndrome (GBS). Further associations between other SARS-CoV-2 vaccines and GBS or Bell palsy have not been clearly demonstrated in large cohort studies, but the possible rare occurrence of Bell palsy following messenger RNA vaccination is a topic of interest. It is also yet to be clearly demonstrated that any other neurological diseases, such as central nervous system demyelinating disease or myasthenia gravis, have any causative association with vaccination against SARS-CoV-2 using any vaccine type, although it is possible that vaccination may rarely trigger a relapse or worsen symptoms or first presentation in already-diagnosed or susceptible individuals.<\/jats:p><\/jats:sec><jats:sec id=\"ab-nrv230003-3\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The associated risk between SARS-CoV-2 vaccination and GBS, and possibly Bell palsy, is slight, and this should not change the recommendation for individuals to be vaccinated. The same advice should be given to those with preexisting neurological autoimmune disease.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaneurol.2023.5208","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T16:02:28Z","timestamp":1705420948000},"page":"179","source":"Crossref","is-referenced-by-count":23,"title":["SARS-CoV-2 Vaccination and Neuroimmunological Disease"],"prefix":"10.1001","volume":"81","author":[{"given":"Alice Grizzel","family":"Willison","sequence":"first","affiliation":[{"name":"Department of Neurology, University Hospital D\u00fcsseldorf, Medical Faculty, Heinrich Heine University, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pawlitzki","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital D\u00fcsseldorf, Medical Faculty, Heinrich Heine University, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Peter","family":"Lunn","sequence":"additional","affiliation":[{"name":"Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom"},{"name":"Department of Neuromuscular Disease, Institute of Neurology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh John","family":"Willison","sequence":"additional","affiliation":[{"name":"College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital D\u00fcsseldorf, Medical Faculty, Heinrich Heine University, D\u00fcsseldorf, Germany"},{"name":"Department of Neurology, Medical University of Vienna, Vienna, Austria"},{"name":"Brain and Mind Center, University of Sydney, Sydney, Australia"},{"name":"Department of Neurology, Palacky University, Olomouc, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G\u00fcnther","family":"Meuth","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital D\u00fcsseldorf, Medical Faculty, Heinrich Heine University, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"nrv230003r1","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/brain\/awac067","article-title":"COVID-19 vaccination and Guillain-Barr\u00e9 syndrome: analyses using the National Immunoglobulin Database.","volume":"146","author":"Keh","year":"2023","journal-title":"Brain"},{"key":"nrv230003r2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3389\/fpubh.2020.00361","article-title":"Do vaccines have a role as a cause of autoimmune neurological syndromes?","volume":"8","author":"Principi","year":"2020","journal-title":"Front Public Health"},{"issue":"2","key":"nrv230003r3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003927","article-title":"First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.","volume":"19","author":"Kerr","year":"2022","journal-title":"PLoS Med"},{"issue":"2","key":"nrv230003r4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003926","article-title":"Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: a population-based cohort study of 46 million adults in England.","volume":"19","author":"Whiteley","year":"2022","journal-title":"PLoS Med"},{"issue":"10045","key":"nrv230003r5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barr\u00e9 syndrome.","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"nrv230003r6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis.","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"issue":"6","key":"nrv230003r7","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1093\/oxfordjournals.aje.a113810","article-title":"Guillain-Barr\u00e9 syndrome and its relationship to swine influenza vaccination in Michigan, 1976-1977.","volume":"119","author":"Breman","year":"1984","journal-title":"Am J Epidemiol"},{"issue":"32","key":"nrv230003r8","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1016\/j.vaccine.2022.06.010","article-title":"Safety of COVID-19 vaccination and acute neurological events: a self-controlled case series in England using the OpenSAFELY platform.","volume":"40","author":"Walker","year":"2022","journal-title":"Vaccine"},{"issue":"12","key":"nrv230003r9","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"nrv230003r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.8879","article-title":"Incidence of Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in the Vaccine Safety Datalink.","volume":"5","author":"Hanson","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"nrv230003r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.53845","article-title":"Reports of Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in the United States.","volume":"6","author":"Abara","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"11","key":"nrv230003r12","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1111\/ene.v29.11","article-title":"Incidence of Guillain-Barr\u00e9 syndrome following SARS-CoV-2 immunization: analysis of a nationwide registry of recipients of 81 million doses of seven vaccines.","volume":"29","author":"Garc\u00eda-Grimshaw","year":"2022","journal-title":"Eur J Neurol"},{"issue":"21","key":"nrv230003r13","doi-asserted-by":"publisher","first-page":"e2094","DOI":"10.1212\/WNL.0000000000207847","article-title":"Risk of Guillain-Barr\u00e9 syndrome following COVID-19 vaccines: a nationwide self-controlled case series study.","volume":"101","author":"Le Vu","year":"2023","journal-title":"Neurology"},{"issue":"52","key":"nrv230003r14","doi-asserted-by":"publisher","first-page":"7579","DOI":"10.1016\/j.vaccine.2022.10.084","article-title":"Guillain-Barr\u00e9 syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.","volume":"40","author":"Osowicki","year":"2022","journal-title":"Vaccine"},{"issue":"16","key":"nrv230003r15","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1001\/jama.2021.16496","article-title":"Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barr\u00e9 syndrome, February-July 2021.","volume":"326","author":"Woo","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"nrv230003r16","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/ana.v90.2","article-title":"Guillain-Barr\u00e9 syndrome following ChAdOx1-S\/nCoV-19 vaccine.","volume":"90","author":"Maramattom","year":"2021","journal-title":"Ann Neurol"},{"key":"nrv230003r17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068373","article-title":"Association between COVID-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.","volume":"376","author":"Li","year":"2022","journal-title":"BMJ"},{"issue":"2","key":"nrv230003r18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2022-000309","article-title":"Guillain-Barr\u00e9 syndrome following SARS-CoV-2 vaccination in the UK: a prospective surveillance study.","volume":"4","author":"Tamborska","year":"2022","journal-title":"BMJ Neurol Open"},{"issue":"24","key":"nrv230003r19","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2023.28.24.2200744","article-title":"Rare cases of Guillain-Barr\u00e9 syndrome after COVID-19 vaccination, Germany, December 2020 to August 2021.","volume":"28","author":"Lehmann","year":"2023","journal-title":"Euro Surveill"},{"issue":"2","key":"nrv230003r20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2022-000378","article-title":"Deciphering changes in the incidence of the Guillain-Barr\u00e9 syndrome during the COVID-19 pandemic: a nationwide time-series correlation study.","volume":"4","author":"Lee","year":"2022","journal-title":"BMJ Neurol Open"},{"issue":"1","key":"nrv230003r21","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1038\/s41598-023-30940-1","article-title":"Real-world data on the incidence and risk of Guillain-Barr\u00e9 syndrome following SARS-CoV-2 vaccination: a prospective surveillance study.","volume":"13","author":"Ha","year":"2023","journal-title":"Sci Rep"},{"issue":"3","key":"nrv230003r22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/jns.v27.3","article-title":"Associations of Guillain-Barr\u00e9 syndrome with coronavirus disease 2019 vaccination: disproportionality analysis using the World Health Organization pharmacovigilance database.","volume":"27","author":"Kim","year":"2022","journal-title":"J Peripher Nerv Syst"},{"issue":"7","key":"nrv230003r23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40261-022-01164-4","article-title":"Guillain-Barr\u00e9 syndrome associated with COVID-19 vaccines: a perspective from spontaneous report data.","volume":"42","author":"Atzenhoffer","year":"2022","journal-title":"Clin Drug Investig"},{"key":"nrv230003r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100236","article-title":"Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell\u2019s palsy: a population-based study.","volume":"11","author":"Shibli","year":"2021","journal-title":"Lancet Reg Health Eur"},{"issue":"7","key":"nrv230003r25","first-page":"997","article-title":"Bell\u2019s palsy: diagnosis and management.","volume":"76","author":"Tiemstra","year":"2007","journal-title":"Am Fam Physician"},{"issue":"5","key":"nrv230003r26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"nrv230003r27","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"nrv230003r28","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1001\/jamainternmed.2021.2219","article-title":"Association of facial paralysis with mRNA COVID-19 vaccines: a disproportionality analysis using the World Health Organization Pharmacovigilance Database.","volume":"181","author":"Renoud","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"14","key":"nrv230003r29","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination.","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"nrv230003r30","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/S1473-3099(21)00273-5","article-title":"Bell\u2019s palsy and SARS-CoV-2 vaccines-an unfolding story.","volume":"21","author":"Cirillo","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"nrv230003r31","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1473-3099(21)00076-1","article-title":"Bell\u2019s palsy and SARS-CoV-2 vaccines.","volume":"21","author":"Ozonoff","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"nrv230003r32","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ijid.2021.08.071","article-title":"Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database.","volume":"111","author":"Sato","year":"2021","journal-title":"Int J Infect Dis"},{"key":"nrv230003r33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ijid.2021.12.346","article-title":"Response to \u201cFacial Nerve Palsy Following the Administration of COVID-19 mRNA Vaccines: Analysis of a Self-Reporting Database\u201d by Sato et al.","volume":"116","author":"O\u2019Fee","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"5","key":"nrv230003r34","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/WCO.0000000000001086","article-title":"Guillain-Barr\u00e9 syndrome in an era of global infections and 21st century vaccination.","volume":"35","author":"Lunn","year":"2022","journal-title":"Curr Opin Neurol"},{"issue":"7","key":"nrv230003r35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41584-023-00964-y","article-title":"High risk of autoimmune diseases after COVID-19.","volume":"19","author":"Sharma","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"nrv230003r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109264","article-title":"Chronic stimulation with SARS-CoV-2 spike protein does not trigger autoimmunity.","volume":"248","author":"Scherlinger","year":"2023","journal-title":"Clin Immunol"},{"issue":"4","key":"nrv230003r37","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1212\/WNL.51.4.1110","article-title":"The spectrum of antecedent infections in Guillain-Barr\u00e9 syndrome: a case-control study.","volume":"51","author":"Jacobs","year":"1998","journal-title":"Neurology"},{"issue":"3","key":"nrv230003r38","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0197-4580(98)00049-9","article-title":"Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis.","volume":"19","author":"Terryberry","year":"1998","journal-title":"Neurobiol Aging"},{"issue":"9","key":"nrv230003r39","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1128\/JVI.02407-10","article-title":"Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.","volume":"85","author":"Geisbert","year":"2011","journal-title":"J Virol"},{"issue":"12","key":"nrv230003r40","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1080\/21645515.2017.1383575","article-title":"Chimpanzee adenoviral vectors as vaccines for outbreak pathogens.","volume":"13","author":"Ewer","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"nrv230003r41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5483\/BMBRep.2022.55.2.183","article-title":"Emerging role of bystander T cell activation in autoimmune diseases.","volume":"55","author":"Shim","year":"2022","journal-title":"BMB Rep"},{"issue":"1","key":"nrv230003r42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/imr.v307.1","article-title":"Silencing and activating anergic B cells.","volume":"307","author":"Tanaka","year":"2022","journal-title":"Immunol Rev"},{"issue":"49","key":"nrv230003r43","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abl8213","article-title":"ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome.","volume":"7","author":"Baker","year":"2021","journal-title":"Sci Adv"},{"issue":"2","key":"nrv230003r44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.seminhematol.2022.02.004","article-title":"Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT).","volume":"59","author":"Greinacher","year":"2022","journal-title":"Semin Hematol"},{"issue":"2","key":"nrv230003r45","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/jns.v26.2","article-title":"Acute and chronic inflammatory neuropathies and COVID-19 vaccines: practical recommendations from the task force of the Italian Peripheral Nervous System Association (ASNP).","volume":"26","author":"Doneddu","year":"2021","journal-title":"J Peripher Nerv Syst"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2813590\/jamaneurology_willison_2024_rv_230003_1707344373.88396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T16:02:03Z","timestamp":1707753723000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2813590"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2023.5208","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}